Antibodies against alpha-synuclein

tools and therapies

Nishant Vaikath, Issam Hmila, Vijay Gupta, Daniel Erskine, Martin Ingelsson, Omar Ali El-Agnaf

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Synucleinopathies including Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are characterized by the abnormal accumulation and propagation of α-synuclein (α-syn) pathology in the central and peripheral nervous system as Lewy bodies or glial cytoplasmic inclusions. Several antibodies against α-syn have been developed since it was first detected as the major component of Lewy bodies and glial cytoplasmic inclusions. Over the years, researchers have generated specific antibodies that alleviate the accumulation of intracellular aggregated α-syn and associated pathology in cellular and preclinical models of synucleinopathies. So far, antibodies have been the first choice as tools for research and diagnosis and currently, a wide variety of antibody fragments have been developed as an alternative to full-length antibodies for increasing its therapeutic usefulness. Recently, conformation specific antibody-based approaches have been found to be promising as therapeutic strategies, both to block α-syn aggregation and ameliorate the resultant cytotoxicity, and as diagnostic tools. In this review, we summarize different α-syn specific antibodies and provide their usefulness in tackling synucleinopathies. (Figure presented.).

Original languageEnglish
JournalJournal of Neurochemistry
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

alpha-Synuclein
Antibodies
Lewy Bodies
Inclusion Bodies
Pathology
Neuroglia
Therapeutics
Synucleins
Multiple System Atrophy
Lewy Body Disease
Immunoglobulin Fragments
Peripheral Nervous System
Neurology
Cytotoxicity
Parkinson Disease
Conformations
Agglomeration
Central Nervous System
Research Personnel
Research

Keywords

  • antibodies
  • synucleinopathies
  • α-synuclein

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Antibodies against alpha-synuclein : tools and therapies. / Vaikath, Nishant; Hmila, Issam; Gupta, Vijay; Erskine, Daniel; Ingelsson, Martin; Ali El-Agnaf, Omar.

In: Journal of Neurochemistry, 01.01.2019.

Research output: Contribution to journalReview article

@article{4a6768eea57a4ae3a222255e029cd2a7,
title = "Antibodies against alpha-synuclein: tools and therapies",
abstract = "Synucleinopathies including Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are characterized by the abnormal accumulation and propagation of α-synuclein (α-syn) pathology in the central and peripheral nervous system as Lewy bodies or glial cytoplasmic inclusions. Several antibodies against α-syn have been developed since it was first detected as the major component of Lewy bodies and glial cytoplasmic inclusions. Over the years, researchers have generated specific antibodies that alleviate the accumulation of intracellular aggregated α-syn and associated pathology in cellular and preclinical models of synucleinopathies. So far, antibodies have been the first choice as tools for research and diagnosis and currently, a wide variety of antibody fragments have been developed as an alternative to full-length antibodies for increasing its therapeutic usefulness. Recently, conformation specific antibody-based approaches have been found to be promising as therapeutic strategies, both to block α-syn aggregation and ameliorate the resultant cytotoxicity, and as diagnostic tools. In this review, we summarize different α-syn specific antibodies and provide their usefulness in tackling synucleinopathies. (Figure presented.).",
keywords = "antibodies, synucleinopathies, α-synuclein",
author = "Nishant Vaikath and Issam Hmila and Vijay Gupta and Daniel Erskine and Martin Ingelsson and {Ali El-Agnaf}, Omar",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jnc.14713",
language = "English",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Antibodies against alpha-synuclein

T2 - tools and therapies

AU - Vaikath, Nishant

AU - Hmila, Issam

AU - Gupta, Vijay

AU - Erskine, Daniel

AU - Ingelsson, Martin

AU - Ali El-Agnaf, Omar

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Synucleinopathies including Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are characterized by the abnormal accumulation and propagation of α-synuclein (α-syn) pathology in the central and peripheral nervous system as Lewy bodies or glial cytoplasmic inclusions. Several antibodies against α-syn have been developed since it was first detected as the major component of Lewy bodies and glial cytoplasmic inclusions. Over the years, researchers have generated specific antibodies that alleviate the accumulation of intracellular aggregated α-syn and associated pathology in cellular and preclinical models of synucleinopathies. So far, antibodies have been the first choice as tools for research and diagnosis and currently, a wide variety of antibody fragments have been developed as an alternative to full-length antibodies for increasing its therapeutic usefulness. Recently, conformation specific antibody-based approaches have been found to be promising as therapeutic strategies, both to block α-syn aggregation and ameliorate the resultant cytotoxicity, and as diagnostic tools. In this review, we summarize different α-syn specific antibodies and provide their usefulness in tackling synucleinopathies. (Figure presented.).

AB - Synucleinopathies including Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are characterized by the abnormal accumulation and propagation of α-synuclein (α-syn) pathology in the central and peripheral nervous system as Lewy bodies or glial cytoplasmic inclusions. Several antibodies against α-syn have been developed since it was first detected as the major component of Lewy bodies and glial cytoplasmic inclusions. Over the years, researchers have generated specific antibodies that alleviate the accumulation of intracellular aggregated α-syn and associated pathology in cellular and preclinical models of synucleinopathies. So far, antibodies have been the first choice as tools for research and diagnosis and currently, a wide variety of antibody fragments have been developed as an alternative to full-length antibodies for increasing its therapeutic usefulness. Recently, conformation specific antibody-based approaches have been found to be promising as therapeutic strategies, both to block α-syn aggregation and ameliorate the resultant cytotoxicity, and as diagnostic tools. In this review, we summarize different α-syn specific antibodies and provide their usefulness in tackling synucleinopathies. (Figure presented.).

KW - antibodies

KW - synucleinopathies

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=85068057351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068057351&partnerID=8YFLogxK

U2 - 10.1111/jnc.14713

DO - 10.1111/jnc.14713

M3 - Review article

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

ER -